Boehringer Ingelheim

INGELHEIM, Germany – June 7, 2026 Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual...

COPENHAGEN, Denmark, June 7, 2026 Zealand Pharma A/S announced that its partner Boehringer Ingelheim presented detailed results from the...

Ingelheim, Germany, May 25, 2026 Boehringer Ingelheim has unveiled new findings from a large international veterinary survey revealing the...

Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that the European Medicines Agency’s Committee for Medicinal Products for...

Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved...

LEXINGTON, Mass., May 21, 2026 Accent Therapeutics has announced the presentation of a Trial in Progress poster for its...

INGELHEIM, Germany & RIDGEFIELD, Conn., May 21, 2026 Boehringer Ingelheim has unveiled significant new oncology data at the 2026...

INGELHEIM, Germany and WALTHAM, Mass., May 12, 2026 Boehringer Ingelheim has entered into a global licensing agreement with Immunitas...

INGELHEIM, GERMANY, April 28, 2026 Boehringer Ingelheim has announced positive Phase III results for its investigational dual agonist survodutide,...

Ingelheim, Germany, April 20, 2026 Boehringer Ingelheim has announced a major strategic expansion of its computational innovation capabilities with...